IMOS
CHIPMOS TECHNOLOGIES INC
$57.66
-9.81%
$2.0B
No data for this timeframe.
Vol
Market Cap$2.0B
Cap SizeMid Cap
Inst. Holders4 funds
Inst. Value$33.8M
Inst. Activity0 buys / 1 sells
SEC Reports8
Recent Activity
Jun 5, 2026
SEC
ChipMOS shareholders approved a cash dividend of NT$1.23 per common share (~US$0.78 per ADS) at the May 26, 2026 AGM. Th
6-K — Impact 3/10
May 26, 2026
SEC
ChipMOS held its 2026 annual shareholders' meeting, ratifying the FY2025 earnings distribution plan, financial statement
6-K — Impact 3/10
May 8, 2026
SEC
ChipMOS reported April 2026 revenue of NT$2,460.5 million (US$77.8 million), up 32.2% YoY but down 1.6% MoM. The strong
6-K — Impact 6/10
Inst.
MORGAN STANLEY — TRIM
1,219 shares ($36.1K)
Inst.
MORGAN STANLEY — NEAR_EXIT
1,689 shares ($32.3K)
Analyst Ratings
4Strong Buy
5Buy
2Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 17, 2015 | Morgan Stanley | DOWNGRADE | Overweight → Equal-Weight |
Latest Reports
NEUTRAL
6-K
3/10
ChipMOS shareholders approved a cash dividend of NT$1.23 per common share (~US$0.78 per ADS) at the May 26, 2026 AGM. Th
Jun 5, 2026
NEUTRAL
6-K
3/10
ChipMOS held its 2026 annual shareholders' meeting, ratifying the FY2025 earnings distribution plan, financial statement
May 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | $33.3M | — |
| BANK OF AMERICA CORP | $405.8K | ADD |
| MORGAN STANLEY | $36.1K | TRIM |
| WELLS FARGO & COMPANY/MN | $8.00 | — |
4 institutional holders with $33.8M total value (1,140,105 shares) as of 2025-Q4. Top holders: RENAISSANCE, BANK, MORGAN. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RENAISSANCE TECHNOLOGIES LLC | 1,125,190 | $33.3M | 98.7% | — |
| 2 | BANK OF AMERICA CORP /DE/ | 13,696 | $405.8K | 1.2% | ADD +71.8% |
| 3 | MORGAN STANLEY | 1,219 | $36.1K | 0.1% | TRIM -27.8% |
| 4 | WELLS FARGO & COMPANY/MN | — | $8.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | TRIM | 1,689 | 1,219 | -27.8% | $36.1K | 2025-Q4 |
| MORGAN STANLEY | NEAR_EXIT | 18,993 | 1,689 | -91.1% | $32.3K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 28,448 | 18,993 | -33.2% | $344.0K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 6,900 | 11,852 | +71.8% | $214.6K | 2025-Q2 |
| UBS Group AG | NEAR_EXIT | 4,626 | 77 | -98.3% | $1.4K | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 3,760 | 28,448 | +656.6% | $479.1K | 2025-Q1 |
| CITADEL ADVISORS LLC | NEW | — | 17,449 | — | $293.8K | 2025-Q1 |
| UBS Group AG | TRIM | 12,228 | 4,626 | -62.2% | $77.9K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 13,990 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | TRIM | 16,587 | 12,228 | -26.3% | $230.3K | 2024-Q4 |
| MORGAN STANLEY | TRIM | 5,026 | 3,760 | -25.2% | $70.8K | 2024-Q4 |
| MORGAN STANLEY | TRIM | 7,276 | 5,026 | -30.9% | $117.6K | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
8 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 1 mixed, 4 neutral. Avg impact: 4.8/10.
NEUTRAL
6-K
3/10
ChipMOS shareholders approved a cash dividend of NT$1.23 per common share (~US$0.78 per ADS) at the
Jun 5, 2026
NEUTRAL
6-K
3/10
ChipMOS held its 2026 annual shareholders' meeting, ratifying the FY2025 earnings distribution plan,
May 26, 2026
BULLISH
6-K
6/10
ChipMOS reported April 2026 revenue of NT$2,460.5 million (US$77.8 million), up 32.2% YoY but down 1
May 8, 2026
BULLISH
6-K
7/10
ChipMOS TECHNOLOGIES INC. disclosed unaudited monthly financial results for February 2026 and audite
Apr 23, 2026
NEUTRAL
6-K
3/10
ChipMOS TECHNOLOGIES INC. issued a 6-K to clarify a Taiwan media report claiming the company expects
Apr 22, 2026
NEUTRAL
6-K
3/10
ChipMOS TECHNOLOGIES INC. disclosed differences between its financial statements prepared under Taiw
Apr 14, 2026
MIXED
20-F
6/10
ChipMOS TECHNOLOGIES INC. reported a 5% year-over-year increase in revenue for 2025, driven by stron
Apr 14, 2026
BULLISH
6-K
7/10
ChipMOS TECHNOLOGIES INC. reported a 23.1% year-over-year increase in March 2026 revenue and a 25.4%
Apr 10, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Nov 2015): 82% buy across 11 analysts — 4 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $7.6B | 32.4% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $8.1B | 32.1% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $30.7B | 28.2% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $33.3B | 8.6% | — |
1 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Nov 17, 2015 | Morgan Stanley | DOWNGRADE | Overweight | Equal-Weight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 5 | 2 | 0 | 0 | 82% | |
| May 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Mar 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Feb 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.